Banerjee, Daipayan
Langberg, Kurt
Abbas, Salar
Odermatt, Eric
Yerramothu, Praveen
Volaric, Martin
Reidenbach, Matthew A.
Krentz, Kathy J. http://orcid.org/0000-0002-4028-4779
Rubinstein, C. Dustin
Brautigan, David L.
Abbas, Tarek
Gelfand, Bradley D.
Ambati, Jayakrishna http://orcid.org/0000-0003-1622-6365
Kerur, Nagaraj http://orcid.org/0000-0001-5040-2129
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 10 February 2021
Accepted: 24 September 2021
First Online: 27 October 2021
Competing interests
: B.D.G., J.A., and N.K. are named as inventors on patent applications on macular degeneration filed by the University of Virginia or the University of Kentucky. J.A. is a co-founder of iVeena Holdings, iVeena Delivery Systems, and Inflammasome Therapeutics and has been a consultant for Allergan, Biogen, Boehringer-Ingelheim, Immunovant, Olix Pharmaceuticals, Retinal Solutions, and Saksin LifeSciences unrelated to this work. J.A. and B.D.G. are co-founders of DiceRx. N.K. and D.L.B. are named as inventors on a patent application on non-canonical signaling activity of cGAMP filed by the University of Virginia. The other authors declare no competing interests.